EBOVAC-3: A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants

The EBOVAC3 project aimed to assess, through clinical trials in children and adults in Africa, the safety and effectiveness of an Ebola vaccine regimen. As such it will help to improve the world’s preparedness to deal with an Ebola outbreak. The project focused on the ‘prime-boost’ Ebola vaccine regimen (Ad26.ZEBOV and MVA-BN-Filo), in which patients were first given a dose to prime the immune system, and then a boost dose which was intended to enhance the immune response over time. Building on work carried out under the EBOVAC1 and 2 projects, EBOVAC3 runed clinical trials in children in Sierra Leone, Guinea and the Democratic Republic of Congo. It also followed up people who participated in earlier clinical trials in Sierra Leone, to assess the safety and efficacy of the vaccine in the longer term. Finally, the project aimed to characterise the outbreak preparedness of Sierra Leone, Guinea and the Democratic Republic of Congo.